Lilly sues two medical spas over copycat weight-loss drugs
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound. The new lawsuits name Thrive Health and Wellness LLC and Valhalla Vitality LLC.
Ozempic 3.0? This drug causes the greatest weight loss — by far
Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective for obese adults who do not have diabetes.
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.
Lilly asks to join lawsuit over compounded versions of its weight-loss drugs
Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.
New Weight Loss Drugs May Fight Obesity-Related Cancer, Too
Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Lilly forecasts weak sales of weight-loss drug in fourth quarter
Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above estimates.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Eli Lilly was hoping weight loss drug demand would be even bigger
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
Some GLP-1s Achieve More Weight Loss Than Others: Study
However, a third drug also FDA-approved for weight loss, liraglutide (Saxenda), didn’t work as well as the others, ...
Medicine Buffalo2d
UB pharmacy professor discusses pros and cons of popular weight-loss drugs
Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...
Miami Herald9d
Ask a Health Professional: How do semaglutide and tirzepatide support wellness goals?
Medications like semaglutide and tirzepatide have gained significant attention for their impressive weight-loss effects, but they do much more than just helping you shed pounds. Let’s dive into ...
krcgtv.com6d
Weight loss options to help New Year's resolutions include GLP-1 injections
The New Year is a time of reflection and change for many Americans, who start each January with a clean slate and goals for ...
Hosted on MSN1d
What is Mounjaro? Everything to know about NHS approved weight loss jab
The Labour Party unveiled plans to introduce the weight-loss jab Mounjaro on the NHS in England in December, aiming to ...
India Today on MSN2d
How Ozempic, Zepbound, and Mounjaro will transform India's weight loss market
The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...